DIVISLAB:NSE-Divi's Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 3,519.35

Change

-142.35 (-3.89)%

Market Cap

INR 989.52B

Volume

1.57M

Avg Analyst Target

INR 5,071.17 (+44.09%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Divi's Laboratories Limited (DIVISLAB) Stock Analysis:
Based on the Divi's Laboratories Limited stock forecasts from 5 analysts, the average analyst target price for Divi's Laboratories Limited is INR 5,071.17 over the next 12 months. Divi's Laboratories Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Divi's Laboratories Limited is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Divi's Laboratories Limited’s stock price was INR 3,519.35. Divi's Laboratories Limited’s stock price has changed by -19.40% over the past week, -20.20% over the past month and -14.12% over the last year.

About

Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and sup ...Read More

Company Website : https://www.divislabs.com

Address : Divi Towers, Hyderabad, India, 500032

Employees : 16,818

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.32

52 Week High : 5,425.10

52 Week Low : 3,497.25

200 Day Moving Average : 4,648.03

50 Day Moving Average : 4,417.61

Shares Held By Insiders : 52.36%

Shares Held by Institutions : 27.40%

Dividend Yield : 0.48%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+1.30 (+0.14%)

 INR2,206.30B 34.35 21.22
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-39.65 (-0.91%)

 INR722.62B 30.73 14.28
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+45.60 (+1.76%)

 INR440.13B 36.09 18.30
PEL:NSE Piramal Enterprises Limited

+2.70 (+0.15%)

 INR422.84B 34.11 11.89
ALKEM:NSE Alkem Laboratories Limited

+37.00 (+1.26%)

 INR354.25B 21.53 15.90
AUROPHARMA:NSE Aurobindo Pharma Limited

-15.45 (-2.87%)

 INR319.92B 11.16 6.57
LAURUSLABS:NSE Laurus Labs Limited

-14.10 (-2.49%)

 INR305.97B 37.09 22.65
LUPIN:NSE Lupin Limited

-10.60 (-1.76%)

 INR279.20B 25.10 71.88
IPCALAB:NSE IPCA Laboratories Limited

-17.60 (-1.84%)

 INR246.36B 26.92 17.53
APLLTD:NSE Alembic Pharmaceuticals Limite..

-17.75 (-2.34%)

 INR151.75B 27.81 16.68

ETFs Containing DIVISLAB

Symbol Name Weight Mer Price(Change) Market Cap
KMED KraneShares Emerging Mark.. 0.00 % 0.80 %

+0.38 (+1.81%)

 INR2.11M
GLIN VanEck Vectors ETF Trust .. 0.00 % 0.82 %

-0.56 (-1.68%)

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.77% 42% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.77% 42% F 26% F
Trailing 12 Months  
Capital Gain -14.13% 58% F 25% F
Dividend Return 0.49% 48% F 28% F
Total Return -13.64% 55% F 25% F
Trailing 5 Years  
Capital Gain 545.40% 96% A 97% A+
Dividend Return 10.27% 95% A 85% B
Total Return 555.67% 96% A 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 52.53% 84% B 84% B
Dividend Return 0.73% 71% C- 52% F
Total Return 53.26% 84% B 84% B
Risk Return Profile  
Volatility (Standard Deviation) 26.77% 91% A- 88% B+
Risk Adjusted Return 198.94% 100% A+ 100% A+
Market Capitalization 989.52B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.54 24% F 26% F
Price/Book Ratio 11.67 7% F 7% F
Price / Cash Flow Ratio 50.82 12% F 12% F
EV/EBITDA 31.87 10% F 18% F
Management Effectiveness  
Return on Equity 23.41% 82% B- 83% B
Return on Invested Capital 23.25% 92% A- 92% A-
Return on Assets 16.71% 97% A+ 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 0.48% 24% F 30% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.32 86% B 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector